Stocksigma LogoStocksigma Logo

Neochem Bio Solutions Delivers Strong H1 FY27 Performance with 50% Top-Line Growth

Neochem reported a 50.4% YoY increase in H1 FY27 revenue from operations to Rs 68.9 Cr, with PAT rising 41.8% YoY to Rs 7.8 Cr (11.4% margin)

Neochem Bio Solutions Delivers Strong H1 FY27 Performance with 50% Top-Line Growth

Neochem Bio Solutions Ltd · Transcript · 03 Nov 2026, 12:06 am

Neochem Bio Solutions Delivers Strong H1 FY27 Performance with 50% Top-Line Growth Neochem reported a 50.4% YoY increase in H1 FY27 revenue from operations to Rs 68.9 Cr, with PAT rising 41.8% YoY to Rs 7.8 Cr (11.4% margin). Volume growth stood at 20% YoY, alongside an annual run-rate capacity utilization of 62%. Receivable days improved to 127 days from 161 days in Mar'26. Operating cash flows normalized significantly to negative Rs 1 Cr versus negative Rs 17 Cr in FY26. Management targets >40% CAGR over the next 5–6 years, with long-term EBITDA and PAT margin bands guided at 18%–20% and 10%–12%, respectively.

Original exchange filing (PDF)

More announcements from Neochem Bio Solutions Ltd

All Neochem Bio Solutions Ltd announcements